NCT03345043View on ClinicalTrials.gov

Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

May 11, 2016

Primary Completion Date

August 13, 2018

Study Completion Date

August 13, 2018

Conditions
Influenza
Interventions
BIOLOGICAL

VAL-339851

Escalating dose levels

OTHER

Placebo

Saline

Trial Locations (1)

33143

Miami Research Associates, Miami

All Listed Sponsors
lead

ModernaTX, Inc.

INDUSTRY

NCT03345043 - Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter